Practical recommendations for pharmacogenomics-based prescription: 2010 ESF–UB Conference on Pharmacogenetics and Pharmacogenomics
- 1 January 2011
- journal article
- Published by Future Medicine Ltd in Pharmacogenomics
- Vol. 12 (1), 113-124
- https://doi.org/10.2217/pgs.10.147
Abstract
The present article summarizes the discussions of the 3rd European Science Foundation–University of Barcelona (ESF–UB) Conference in Biomedicine on Pharmacogenetics and Pharmacogenomics, which was held in June 2010 in Spain. It was focused on practical applications in routine medical practice. We provide practical recommendations for ten different clinical situations, that have either been approved or not approved by regulatory agencies. We propose some comments that might accompany the results of these tests, indicating the best drug and doses to be prescribed. The discussed examples include KRAS, cetuximab, panitumumab, EGFR–gefitinib, CYP2D6–tamoxifen, TPMT–azathioprine–6-mercaptopurine, VKORC1/CYP2C9–warfarin, CYP2C19–clopidogrel, HLA-B*5701–abacavir, HLA-B*5701–flucloxacillin, SLCO1B1–statins and CYP3A5–tacrolimus. We hope that these practical recommendations will help physicians, biologists, scientists and other healthcare professionals to prescribe, perform and interpret these genetic tests.Keywords
This publication has 44 references indexed in Scilit:
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaThe New England Journal of Medicine, 2009
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal CancerThe New England Journal of Medicine, 2009
- Genetic Determinants of Response to Clopidogrel and Cardiovascular EventsThe New England Journal of Medicine, 2009
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal CancerThe New England Journal of Medicine, 2008
- Detection of Mutations inEGFRin Circulating Lung-Cancer CellsThe New England Journal of Medicine, 2008
- HLA-B*5701 Screening for Hypersensitivity to AbacavirThe New England Journal of Medicine, 2008
- The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancerThe Pharmacogenomics Journal, 2007
- 5-Fluorouracil-related severe toxicity: A comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiencyCancer Letters, 2007
- Erlotinib in Lung Cancer — Molecular and Clinical Predictors of OutcomeThe New England Journal of Medicine, 2005
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibThe New England Journal of Medicine, 2004